SEARCH

SEARCH BY CITATION

References

  • 1
    Weiss S, Goldblum J. General considerations. In: WeissS, GoldblumJ, eds. Enzinger and Weiss's Soft Tissue Tumors. St Louis, Missouri: CV Mosby; 2001: 1-19.
  • 2
    Weiss S, Goldblum J. Malignant soft tissue tumors of uncertain type. In: WeissS, GoldblumJ, eds. Enzinger and Weiss's Soft Tissue Tumors. St Louis, Missouri: CV Mosby; 2001: 1483-1571.
  • 3
    Mancuso T, Mezzelani A, Riva C, et al. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest. 2000; 80: 805-813.
  • 4
    Mezzelani A, Mariani L, Tamborini E, et al. SYT-SSX fusion genes and prognosis in synovial sarcoma. Br J Cancer. 2001; 85: 1535-1539.
  • 5
    FletcherKU, MertensF, eds. WHO Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
  • 6
    Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004; 22: 4040-4050.
  • 7
    Bozzi F, Ferrari A, Negri T, et al. Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation. Transl Oncol. 2008; 1: 95-101.
  • 8
    Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in paediatric age: a nomogram-based prognostic comparison with adult sarcoma. Eur J Cancer. 43: 2691-2697, 2007.
  • 9
    Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004; 101: 627-634.
  • 10
    Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973-2005 varying) - Linked To County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission. (www.seer.cancer.gov).
  • 11
    Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer. 1993; 71: 3647-3655.
  • 12
    Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: the St Jude Children's Research Hospital experience. J Clin Oncol. 1994; 12: 2360-2366.
  • 13
    Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol. 1999; 32: 32-37.
  • 14
    Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003; 21: 1602-1611.
  • 15
    Ferrari A, Bisogno G, Alaggio R, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cance. 2008; 44: 1202-1209.
  • 16
    Brodsky JT, Burt ME, Hajdu SI, Casper ES, Brennan MF. Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis. Cancer. 1992; 70: 484-489.
  • 17
    Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999; 85: 2596-2607.
  • 18
    Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000; 18: 3794-3803.
  • 19
    Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000; 18: 2087-2094.
  • 20
    Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001; 19: 525-534.
  • 21
    Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas. Expert Rev Anticancer Ther. 2008; 8: 929-938.
  • 22
    Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised soft-tissue sarcoma in adults (Cochrane Review). Oxford UK: The Cochrane Library, Update Software; 2003.
  • 23
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 1238-1247.
  • 24
    Kampe CE, Rosen G, Eilber F, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer. 1993; 72: 2161-2169.
  • 25
    Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994; 73: 2506-2511.
  • 26
    Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. Mar. 2005; 16: 437-444.
  • 27
    Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007; 246: 105-113.
  • 28
    Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 69: 1173-1180.
  • 29
    Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996; 78: 656-663.
  • 30
    Meis-Kindblom JM, Bjerkehage B, Bohling T, et al. Morphologic review of 1000 soft tissue sarcomas from the Scandinavian Sarcoma Group (SSG) Register. The peer-review committee experience. Acta Orthop Scand Suppl. 1999; 285: 18-26.
  • 31
    Presant CA, Russell WO, Alexander RW, Fu YS. Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience. J Clin Oncol. 1986; 4: 1658-1661.
  • 32
    Tamborini E, Bonadiman L, Greco A, et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res. 2004; 10: 938-943.
  • 33
    Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005; 103: 830-838.
  • 34
    Albritton KH, Randall RL. Prospects for targeted therapy of synovial sarcoma. J Pediatr Hematol Oncol. 2005; 27: 219-222.